Rotavirus vaccine - MAXVAX Biotechnology
Latest Information Update: 20 Feb 2023
At a glance
- Originator MAXVAX Biotechnology
- Class Rotavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Rotavirus infections
Most Recent Events
- 14 Dec 2022 MAXVAX Biotechnology plans for launch of Rotavirus vaccine in 2025 (MAXVAX Biotechnology pipeline, December 2022)
- 14 Dec 2022 MAXVAX Biotechnology plans for NDA filling for Rotavirus vaccine in 2024 (MAXVAX Biotechnology pipeline, December 2022)
- 14 Dec 2022 MAXVAX Biotechnology plans a phase III trial for Rotavirus vaccine (Parenteral) (MAXVAX Biotechnology pipeline, December 2022)